Drug Oncology

Pemfexy

Payments companies reported to CMS as associated with Pemfexy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$11Kassociated payments (2023-2025)

94clinicians with associated payments

1company reporting

By year

2023 $3,364

2024 $7,919

Payments reported as associated with Pemfexy, per program year, as reported to CMS.

Who makes it

Eagle Pharmaceuticals, INC. $11K associated with Pemfexy (2023-2025)

Specialties most often involved

Hematology & Oncology $2,926

Family $1,294

Internal Medicine $1,037

Medical Oncology $1,025

Gynecologic Oncology $895

Radiation Oncology $775

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Pemfexy

These are the largest totals companies reported as associated with Pemfexy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Daron Street	Tulsa, OK	Gynecologic Oncology	$722.64
Nashat Gabrail	Canton, OH		$356.70
Jeffrey Patton	Nashville, TN	Medical Oncology	$309.63
Rachel Prytula	Dothan, AL	Acute Care (Nurse Practitioner)	$207.66
John Dunn	Dothan, AL	Hematology & Oncology	$207.66
Allison Mcallister	Dothan, AL	Nurse Practitioner	$207.65
Candice Bertsch	Dothan, AL	Family	$207.65
Sramila Aithal	Bensalem, PA	Medical Oncology	$204.43
Moshe Chasky	Philadelphia, PA	Hematology & Oncology	$204.42
Allen Terzian	Philadelphia, PA	Hematology & Oncology	$204.41

Prescribed Pemfexy?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.